Loading data for PALI — first visit, this takes a few seconds.

アラート

Palisade Bio Inc. (PALI)

NasdaqCM: PALI · リアルタイム株価 · USD

2.07

+0.06 (2.99%)

終値時点： Aug 25, 2026, 3:59 PM

2.11

+1.93%

寄り付き前: 4:01 AM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

2.99% (1D)

買気配	1.48
時価総額	360.74M
売上高（TTM）	500K
純利益（TTM）	-31.94M
	1.54
	0.67
	3.09
	-7.39
PBR（TTM）	2.95
PSR（TTM）	721.48
決算発表日	n/a

売気配	2.56
出来高	2,067,764
平均出来高（20日）	2,999,450
始値	2.05
前日終値	2.01
当日レンジ	1.98 - 2.10
52週レンジ	0.53 - 2.86
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

PALIについて

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research c...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Mar 30, 2007

従業員数 14

上場取引所 NasdaqCM

ティッカー PALI

ウェブサイト https://www.palisadebio.com

企業情報の全文

業績

2025年のPalisade Bioの売上高は0で、前年の0からundefined%の増加でした。利益は-16.78Mで、16.23%の増加でした。

財務諸表

決算サプライズ

Palisade BioはAug 10, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
EPSは -0.05 で、予想を下回りました 0.00, うち 92.75% の前年比増加にあたります.

ニュース

4週間前 · Benzinga

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market. The company...

1か月前 · Stocktwits

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

3か月前 · Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

3か月前 · Motley Fool

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

3か月前 · Insider Monkey

Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M

Palisade Bio Inc. (NASDAQ:PALI) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, Palisade reported Q1 2026 earnings, recording a net increase in operating expenses to fund its cl...

2ページ中1ページ

Palisade Bio Inc. (PALI)